Zarębska-Michaluk, D.; Jaroszewicz, J.; Parfieniuk-Kowerda, A.; Janczewska, E.; Dybowska, D.; Pawłowska, M.; Halota, W.; Mazur, W.; Lorenc, B.; Janocha-Litwin, J.;
et al. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J. Clin. Med. 2021, 10, 3280.
https://doi.org/10.3390/jcm10153280
AMA Style
Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J,
et al. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. Journal of Clinical Medicine. 2021; 10(15):3280.
https://doi.org/10.3390/jcm10153280
Chicago/Turabian Style
Zarębska-Michaluk, Dorota, Jerzy Jaroszewicz, Anna Parfieniuk-Kowerda, Ewa Janczewska, Dorota Dybowska, Małgorzata Pawłowska, Waldemar Halota, Włodzimierz Mazur, Beata Lorenc, Justyna Janocha-Litwin,
and et al. 2021. "Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics" Journal of Clinical Medicine 10, no. 15: 3280.
https://doi.org/10.3390/jcm10153280
APA Style
Zarębska-Michaluk, D., Jaroszewicz, J., Parfieniuk-Kowerda, A., Janczewska, E., Dybowska, D., Pawłowska, M., Halota, W., Mazur, W., Lorenc, B., Janocha-Litwin, J., Simon, K., Piekarska, A., Berak, H., Klapaczyński, J., Stępień, P., Sobala-Szczygieł, B., Citko, J., Socha, Ł., Tudrujek-Zdunek, M.,
... Flisiak, R.
(2021). Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. Journal of Clinical Medicine, 10(15), 3280.
https://doi.org/10.3390/jcm10153280